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Pharmaceutical treatment can be inadequate, non-effective, or intolerable for many people suffering
from a neuronal channelopathy. Development of novel treatment options, particularly those with the
potential to be curative is warranted. Gene therapy approaches can permit cell-speciﬁc modiﬁcation of
neuronal and circuit excitability and have been investigated experimentally as a therapy for numerous
neurological disorders, with clinical trials for several neurodegenerative diseases ongoing. Channelo-
pathies can arise from a wide array of gene mutations; however they usually result in periods of aberrant
network excitability. Therefore gene therapy strategies based on up or downregulation of genes that
modulate neuronal excitability may be effective therapy for a wide range of neuronal channelopathies. As
many channelopathies are paroxysmal in nature, optogenetic or chemogenetic approaches may be well
suited to treat the symptoms of these diseases. Recent advances in gene-editing technologies such as the
CRISPR-Cas9 system could in the future result in entirely novel treatment for a channelopathy by
repairing disease-causing channel mutations at the germline level. As the brain may develop and wire
abnormally as a consequence of an inherited or de novo channelopathy, the choice of optimal gene
therapy or gene editing strategy will depend on the time of intervention (germline, neonatal or adult).
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Genetic channelopathies result from loss or gain of function
mutations in genes coding ion channels or their accessory subunits.
For the majority of channelopathies, therapy is palliative, treating
either the symptoms of the disease, or using drugs which target the
mutated ion channel. In either case, for a signiﬁcant number of
patients, therapy is often limited due to a lack of efﬁcacy and
tolerability. As many drugs that target speciﬁc families of ion
channels are unable to discriminate between ion channel isoforms,
they usually result in unwanted or unacceptable side-effects. The
number of recognised genetic channelopathies, either inherited or
de novo, is increasing as testing becomes more routine. Many
channelopathies are extremely rare, and although pharmaceutical
companies run rare/ultra-rare disorders programs, the develop-
ment of alternative therapies is warranted. Therefore for the
treatment of channelopathies, it may be prudent to move away
from traditional drug-discovery programs and focus on the devel-
opment of gene therapy and gene editing tools that can be tailored
to the needs of each individual person. Gene therapy approaches
can permit cell-speciﬁc modiﬁcation of neuronal and circuit excit-
ability and have been investigated experimentally as a therapy for
numerous neurological disorders (Simonato et al., 2013). Recent
advances in gene-editing technologies such as the CRISPR-Cas9
system could in the future result in entirely novel treatment for a
channelopathy by repairing disease-causing channel mutations at a
genomic level (McMahon and Cleveland, 2017).
2. Classical gene therapy approaches
Proof-of-concept studies in cell cultures and animal models
have demonstrated the effectiveness of gene therapy in treating
many neurological disorders, usually by either overexpression of a
therapeutic gene, by either boosting expression of the non-mutated
wild-type gene or by expressing a gene unrelated to the channel-
opathy that permits improvement of pathology. Alternatively one
could inhibit the expression of the disease causing gene if the
mutation is gain of function, such as for SCN8A mutations related
with early-infantile epileptic encephalopathies (Wagnon and
Meisler, 2015). Recently there has been signiﬁcant progress in the
advancement of the molecular tools required to translate these
genetic strategies in experimental models to treat patients with a
wide-range of neurological syndromes including, Parkinson's dis-
ease, Alzheimer's disease, Huntington's disease and epilepsy
(Simonato et al., 2013; Choong et al., 2016). Gene therapy clinical
trials for many of these diseases have already commenced. Few of
these phase I/II clinical trials have so far reported signiﬁcant clinical
beneﬁt (O'Connor and Boulis, 2015; Blits and Petry, 2016), although
some are encouraging (LeWitt et al., 2011). With further basic sci-
ence improvements in transgene vector design and delivery, and
the identiﬁcation of new therapeutic targets, there is optimism that
results from ongoing and future trials will provide more favourable
clinical outcomes.
2.1. Modulating neuronal excitability
Neuronal channelopathies often result in alterations in action
potential properties and/or synaptic transmission resulting in an
aberrant cellular and network excitability. The resultingPlease cite this article in press as: Wykes, R.C., Lignani, G., Gene therapy a
Neuropharmacology (2017), http://dx.doi.org/10.1016/j.neuropharm.2017pathological phenotype will depend on the expression pattern of
the ion channel or accessory subunit that is mutated and the
functional consequence of this mutation. A key feature of these
diseases is that they are often paroxysmal in nature (Kullmann,
2010). Epilepsy is a disease characterised by discreet episodes of
network hyper-excitability and although there are many distinct
mechanisms that can cause epilepsy some result from monogenic
mutations in different classes of neuronal ion channels (Lerche
et al., 2013; Snowball and Schorge, 2015; Spillane et al., 2016).
Therefore gene therapy strategies based on modulating either
cellular or circuit excitability proven to be effective in experimental
models of epilepsy may also be promising approaches to treat a
broad range of channelopathies. Over the last decade there have
been many experimental studies investigating gene therapy ap-
proaches to prevent epileptogenesis or treat established epilepsy
(Simonato, 2014). The majority of these studies have not used an-
imal models of epilepsy that arise from inherited mutations of ion
channels with widespread brain expression. Instead, for reasons
mainly associated to limited transduction volume of the viral vec-
tors used to deliver the transgenes, they have focused on acquired
epilepsies with a discreet epileptogenic zone (Wykes et al., 2012;
Kullmann et al., 2014). Gene therapy approaches to treat epilepsy
include targeting inﬂammatory pathways (Mazzuferi et al., 2013),
preventing neuronal damage (Paradiso et al., 2009, 2011; Bovolenta
et al., 2010) or manipulating expression of whole cohorts of genes
that change during epileptogenesis by modulating transcription
factors or microRNAs (McClelland et al., 2011; Jimenez-Mateos
et al., 2012). However three main strategies investigated, based
on manipulating neuronal excitability, can potentially be applied to
treat abnormal network excitability resulting from a given neuronal
channelopathy. The ﬁrst is to increase inhibitory tone via increased
expression of inhibitory neuropeptides or adenosine. The second
involves manipulating intrinsic cell excitability by increasing or
decreasing expression of ion channel genes. The third relies on
expression of an exogenous ion channel or receptor, which when
activated by a speciﬁc ligand, can result in neuronal ﬁring or
silencing.
2.2. Increasing inhibitory tone
Increasing expression of a number of inhibitory neuropeptides
including galanin and neuropeptide Y (NPY), either in isolation or
together with inhibitory Y receptor type 2, has been shown to
exhibit anticonvulsant properties (Haberman et al., 2003; Richichi
et al., 2004; Lin et al., 2006; McCown, 2006; Woldbye et al.,
2010). A conceptual advantage to this approach is that the
expression of the neuropeptides does not need to be restricted to
speciﬁc cell types. Secretion of an inhibitory neuropeptide could
affect targets remote from their site of release. Increasing NPY
levels in the hippocampus was effective in reducing spontaneous
seizure frequency in models of temporal lobe epilepsy (Noe et al.,
2007; Ledri et al., 2016). Adenosine is an endogenous brain anti-
convulsant and increasing levels of this protein by siRNA mediated
knockdown of adenosine kinase has been reported to reduce
spontaneous seizures (Theoﬁlas et al., 2011). Although dosage
control is more difﬁcult with gene therapy than pharmaceutic
compounds, there are numerous advantages to gene therapy
including cell speciﬁcity and either constitutive or long-lasting
effects.nd editing: Novel potential treatments for neuronal channelopathies,
.05.029
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At a cellular level, overexpression of an inhibitory ion channel,
such as the a1 subunit of the g-aminobutyric acid (GABAA) receptor
(Raol et al., 2006), has been reported to decrease the number of
seizures observed following a period of status epilepticus. Alter-
natively, decreasing excitability of pyramidal neurons by over-
expression of the potassium channel KV1.1 was effective in
suppressing established epileptiform activity (Wykes et al., 2012).
An alternative approach would be to reduce pyramidal neuron
excitability by reducing the expression of sodium channels using
siRNA techniques (Boison, 2010). For these strategies to be effective
the transgenes must be expressed only in speciﬁc populations of
neurons, principle (excitatory) or interneuron (inhibitory), other-
wise the opposite of the desired effect may occur (Haberman et al.,
2002).
With these approaches, changes in inhibitory tone or ion
channel expression, it will be difﬁcult to quantify how much
overexpression or siRNA-mediated reduction in protein will be
required for the treatment of the pathology. Additionally, it is not
known whether a sustained increase or decrease in expression
levels of a certain protein will result in homeostatic compensation,
or alterations in normal physiology and behaviour. The regulation
of therapeutic function is not easily controllable as the expression
of the exogenous gene is dependent on the promoter used which
may have a different activity to the endogenous promoter of that
gene.
2.4. Optogenetics and chemogenetics
Many patients with a channelopathy often appear normal be-
tween episodes of attack, presumably due to homeostatic mecha-
nisms that are able to regulate membrane excitability within
acceptable limits (Ryan and Ptacek, 2010). However when stressed
in some way these homeostatic mechanisms are no longer able to
keep the network within normal excitability parameters. Examples
of a precipitating factor include consumption of certain foods that
raise or lower serum potassium in channelopathies that result in
periodic paralyses or warm temperatures in channelopathies that
result in erythermelalgia (Ryan and Ptacek, 2010; Swann and Rho,
2014).
In this respect, instead of permanently up or down regulating
proteins as suggested above we could focus on developing new
therapies that can ‘on-demand’ reset network excitability only
when required to do so.
Optogenetics is the combination of optical and genetic methods
to control the activity of speciﬁc populations of excitable cells by
light with high temporal and spatial resolution (Deisseroth, 2010).
Derived from microbial organisms ‘opsin’ genes encoding light-
activated ion channels and pumps can be genetically targeted to
deﬁned neuronal populations in mammalian brains using viral
vectors. When exposed to light of an appropriate wavelength,
activation or inhibition of neuronal excitability can be optically
induced on a millisecond timescale (Fenno et al., 2011). In vivo
epilepsy-related optogenetic research has focused on expressing
inhibitory opsins (halorhodopsin) in excitatory principal neurons
(Wykes et al., 2012; Krook-Magnuson et al., 2013; Paz et al., 2013;
Sukhotinsky et al., 2013; Berglind et al., 2014; Sorokin et al., 2017)
or excitatory opsins (Channelrhodopsin) in inhibitory interneurons
within the epileptic focus (Krook-Magnuson et al., 2013; Chiang
et al., 2014; Ladas et al., 2015; Assaf and Schiller, 2016). Although
other approaches include optogenetically targeting structures that
project to areas involved in seizure initiation (Krook-Magnuson
et al., 2014, 2015; Kros et al., 2015; Soper et al., 2016; Xu et al.,
2016). Optogenetic approaches have successfully suppressedPlease cite this article in press as: Wykes, R.C., Lignani, G., Gene therapy a
Neuropharmacology (2017), http://dx.doi.org/10.1016/j.neuropharm.2017seizure activity in vivo although there is an as yet unresolved debate
as to which are the best subpopulations of interneurons to activate
and when during periods of ictal and inter-ictal activity it is best to
activate them (Wykes et al., 2016). There are translational concerns
speciﬁc to a gene therapy approach based on optogenetics,
including safety issues, concerning an immunological response, in
regard to long-term expression of non-mammalian proteins and
the need for a light source to be implanted into the brain. As brain
penetrance by light is poor this approach is only likely to be feasible
where optical stimulation of neurons in a focal area of the brain is
required (Wykes et al., 2016). However the ability to use opto-
genetic technology to turn light-gated ion channels or pumps on
and off only in response to changes in pathological brain network
excitability is an attractive proposal for patients with an episodic
neuronal channelopathy. This will allow brain circuits to operate
normally at other times avoiding the side-effects of drugs or any
potential adverse behaviour due to chronic up or downregulation of
endogenous proteins.
Chemogenetics is a term used to describe the mutation of a
ligand binding site in an ion channel or G protein-coupled receptor
(GPCR) rendering the protein unable to respond to the endogenous
ligand, but enabling it to be activated by an exogenous ligand. These
mutated proteins are referred to as designer receptors exclusively
activated by a designer drug (DREADD) (Roth, 2016). Speciﬁcity of
DREADDs can be achieved by regional and cell-type speciﬁc
expression using viral vectors. Neurons transduced to express a
chemogenetic protein are not permanently altered in their intrinsic
properties, but can respond with changes in neuronal excitability
when a speciﬁc exogenous ligand is delivered (Pei et al., 2010). In
contract to optogenetic techniques where invasive light delivery is
required to activate the channels or pumps, the exogenous ligands
used to activate DREADDs can usually be delivered systemically.
Additionally this approach allows for larger and deeper areas of the
brain to be targeted for modulation compared to optogenetics. A
prototypical example of a DREADD is the engineered inhibitory Gi-
coupled human muscarinic receptor hM4Di which has been
rendered insensitive to the endogenous ligand acetylcholine and
sensitive to a metabolically inert derivative of clozapine, clozapine-
N-oxide (CNO) (Armbruster et al., 2007; Ferguson and Neumaier,
2012). hM4Di activation results in opening of G-protein gated
inwardly rectifying potassium channels inducing neuronal inhibi-
tion via membrane hyperpolarization (Armbruster et al., 2007).
CNO-mediated activation of hM4Di expressed in principle neuro-
nes within the epileptic focus was shown to inhibit acute and
spontaneous seizures in rodent models of epilepsy (Katzel et al.,
2014). Whereas optogenetic control of neurons can be achieved
on the millisecond timescale, modulation of neuronal excitability
via chemogenetic methods is orders of magnitude slower (minutes
to hours). Chemogenetic approaches could be highly suitable in the
treatment of a paroxysmal channelopathy such as migraine when a
known precipitating factor such as hormonal ﬂuctuation has been
identiﬁed as a trigger. Formanywomen, migraines are connected to
their menstrual cycle, occurring for a few days when estrogen
levels drop (Martin and Lipton, 2008). In fact as many as 1 in 4
people with migraine experience a prodromal phase, which can
occur as early as 24 h before the migraine starts. For these patients
brain areas can be transduced with a DREAAD and the orally
bioavailable ligand taken to coincide with the start of menstruation
or at the onset of prodromal symptoms.
A major advantage of both of these techniques is that they are
potentially amenable to a closed-loop design by coupling abnormal
network excitability to delivery of the ligand (light in the case of
optogenetics and agonist in the case of chemogenetics). Advances
in closed-loop, on-demand systems that recognize diverse human
epileptic EEG signatures will be required, as will the developmentnd editing: Novel potential treatments for neuronal channelopathies,
.05.029
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long-life battery. Implantable devices capable of real-time seizure
detection and light emission in rodents are now being developed
(Armstrong et al., 2013 and Kullmann DM&Wykes RC, unpublished
data) and such devices, if successfully translated, offer the prospect
of a device similar to an automatic implantable cardiac deﬁbrillator
to stop seizures without the permanent alteration of neuronal
properties.
3. The gene editing challenge
An ideal treatment for a genetic channelopathy would be the
ability to edit the faulty gene and correct the mutations(s). Gene
editing is an exciting and promising gene therapy approach as this
strategy offers the prospect of not only treating a channelopathy
but curing the disease permanently. However, there are several
limitations, in particular for neurological application of these
techniques, which will have to be overcome before a translational
breakthrough (Heidenreich and Zhang, 2016; Lee et al., 2016).
Several molecular mechanisms exist that can potentially correct
the protein product of a faulty gene. These include RNA repair
mechanisms which work at the level between the gene and the
protein such as Spliceosome-Mediated RNA Trans-Splicing (Yang
and Walsh, 2005), and gene editing tools such as ZFN, TALEN, and
CRISPR/Cas (Kim and Kim, 2014). Of these CRISPR/Cas may be best
suited to allow translational therapy for pathologies caused by
genetic modiﬁcations (Sander and Joung, 2014) and will be dis-
cussed further. CRISPR is an innate protective mechanism part of
the bacteria and archaea immune system, and it functions to pro-
tect them from viral and plasmid attacks (Horvath and Barrangou,
2010; Wiedenheft et al., 2012; Wright et al., 2016). Engineering of
this system a few years ago permitted gene editing in mammalian
cells (Cong et al., 2013; Mali et al., 2013). The CRISPR system is
composed of two distinct parts: a nuclease (e.g. Cas9) able to cut
the double DNA strand, and a small guide RNA (gRNA) which drives
the nuclease in a precise genome location (Sander and Joung, 2014;
Wright et al., 2016). This permits a precise double strand break of
the DNA in a deﬁned genome region.
Thereafter, at least two innate cell mechanisms of DNA repairing
can be activated, the homology-directed repair (HDR) and the non-
homologous end joining (NHEJ) (Sander and Joung, 2014). HDR
requires the presence of an appropriately designed DNA repair
template and corrects the break without introducing errors,
essentially replacing the short stretch of faulty DNA with a cor-
rected version. NHEJ is an error-prone mechanism of repair,
frequently introducing insertion/deletion mutations, but does not
require a DNA template (Sander and Joung, 2014; Chu et al., 2015;
Maruyama et al., 2015). In neurons, and in general in all post-
mitotic cells, HDR is less active than NHEJ (Cox et al., 2015). For
this reason, at themoment, using HDR as a gene editing tool to treat
neurons in vivo is still a big challenge (Heidenreich and Zhang,
2016; Lee et al., 2016).
In addition to potentially treating neurological diseases,
genome-editing technology can be used to provide a greater un-
derstanding of diseases themselves (Heidenreich and Zhang, 2016;
Lee et al., 2016). HDR has already been used to generate animal
models of neurological diseases (Niu et al., 2014; Heidenreich and
Zhang, 2016) as well as to insert or correct single mutations in
cell lines and in induced pluripotent stem cells (iPSC) facilitating
the investigation of channelopathies such as Dravet Syndrome (Liu
et al., 2016). Although iPSC-derived neurons are a fundamental
model to study neurological diseases and CRISPR considerably
improved their potentiality (Heidenreich and Zhang, 2016; Rubio
et al., 2016), an in vivo approach to understand the pathological
effects of neuronal channelopathies on complex connectedPlease cite this article in press as: Wykes, R.C., Lignani, G., Gene therapy a
Neuropharmacology (2017), http://dx.doi.org/10.1016/j.neuropharm.2017networks is required. As homeostatic and developmental changes
are likely to occur as a result of a channelopathy, gene editing
in vivo in animal models will be crucial to determine at which stage
in an animals life, (embryonic, neonatal, adult), correction of the
faulty gene will result in a full reversal of pathology.
CRISPR has been already successfully applied in vivo and in vitro
in post-mitotic neurons mostly to disrupt gene function, such as
those that code for iontropic neurotransmitter receptors (NMDA
and AMPA), or proteins implicated in neurological disease such as
the silencing factor MECP2 (Incontro et al., 2014; Straub et al., 2014;
Swiech et al., 2015). Moreover, modiﬁed CRISPRs, not able to cut the
DNA but still able to target a defective Cas9 (dCas9) to a precise
genome location, have been used to increase or decrease gene
expression by fusing cas9 with activator or repressor elements, as
well as epigenetically controlling gene transcription by fusing cas9
with chromatin regulator factors (Qi et al., 2013; Hilton et al., 2015).
Although the use of CRISPR/Cas9 in post-mitotic cells is limited by
HDR low activity, recently two similar approaches, based on NHEJ,
opened new possibilities for gene editing in vivo (Nakade et al.,
2014; Suzuki et al., 2016). Suzuki et al. demonstrated for the ﬁrst
time that using homology-independent targeted integration (HITI),
based on NHEJ, it is possible to precisely insert a DNA sequence in a
genome location in neurons in vivo using CRISPR/Cas9 (Suzuki et al.,
2016). HITI successfully improved vision in a rat model of the
retinal degeneration condition retinitis pigmentosa providing proof
of principle that a gene therapy approach based on CRISPR/Cas9 can
treat a neurological genetic disease. In this study a copy of a non-
mutated exon 2 was inserted into the ﬁrst intron of the faulty
gene. Importantly this was achieved in mature neurons (Suzuki
et al., 2016). The big challenge will be to precisely correct single
mutations in ion channels in neurons. This approach could rescue
severe channelopathies due to mutations in channels such as
SCN1A, SCN2A, KCNQ2/3, CACNA1, KCN1A or GABRA1 which at
present have few or no effective treatment options (Kullmann and
Waxman, 2010; Spillane et al., 2016). The direct modiﬁcation of the
single mutation in an ion channel gene, the disruption of a faulty
gene as well as the regulation of endogenous gene expression have
advantages compared to the current strategies such as drug
administration, optogenetics, chemogenetics, channel over-
expression or RNA interference. However several challenges exist
which must be overcome before gene editing can be used to rescue
both acquired and genetic channelopathies (Bernard et al., 2004;
Heidenreich and Zhang, 2016; Spillane et al., 2016). Some limita-
tions are shared with “classical” gene therapy approaches (e.g. viral
transduction efﬁciency, see below) others are more speciﬁc such as
the size of the Cas9 or the possibility of off-target recognition by
sequences of the gRNAs (Heidenreich and Zhang, 2016; Lee et al.,
2016; Suzuki et al., 2016). Continued development of viral vectors
and new CRISPR systems (saCAS9, SpCas9-HF1) are helping to
overcome these limitations (Heidenreich and Zhang, 2016;
Kleinstiver et al., 2016; Wright et al., 2016). Regarding the HITI
and in general the gene editing mediated by NHEJ, it will be
important to determine whether the inclusion of a few base pairs
before and after the reintroduced nucleotide sequence will alter
post-translational modiﬁcations to the channel and/or affect cor-
rect protein trafﬁcking (Suzuki et al., 2016). Although there may be
the possibility of gene editing at an embryonic stage (Callaway,
2016b) for genetic channelopathies, it is most likely, and only
possible for acquired channelopathies, to use a viral approach to
target CRISPR-Cas nucleases to multiple neurons in the mature
brain. CRISPR development could permit a new era of treatments
for neurological channelopathies. The ideal system would be to
revert back to wild-type amino acid sequences. However with
current methodology, additional amino nucleotides may be intro-
duced. In this context it is important to insure that the codingnd editing: Novel potential treatments for neuronal channelopathies,
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proteins such as ion channels.
4. Viral vector mediated delivery of gene therapies into
neurons
The efﬁcacy of a neuronal gene therapy strategy will depend on
targeting disease-modifying agents to where they need to be, not
only transduction of the correct cells and circuits but also to the
appropriate intracellular localization. A viral strategy for the de-
livery of a therapeutic gene or gene-editing tools into a neuron is
most likely, although alternatives such as liposomes or nanoparticle
mediated delivery can also be considered (Naldini, 2015). The key to
development of an effective viral vector is to harness the virus
biology for transgene expression and to modify or remove the
remaining viral genome in a manner that prevents pathogenic
properties such as viral replication after host transduction. A
number of genetically modiﬁed viruses are being developed that
can be used to introduce heterologous genes or sequences of DNA
into neurons in a safe manner. At present twomain classes aremost
prominent: the lentiviruses and the adeno-associated viruses
(AAVs). Other viruses transduce neurons, but can produce unac-
ceptable toxicity, immune responses or transient transgene
expression (HSV, Rabies, semliki forest virus) (Manfredsson and
Mandel, 2010). In this article we will discuss the suitability of len-
tiviruses and AAVs to treat CNS channelopathies. However it should
be noted that there are channelopathies which affect the PNS
where a different viral approach may be preferential. For example
non-replicating Herpes Simplex viruses are promising vehicles for
delivery of therapeutic transgenes to the PNS (Glorioso and Fink,
2004).
4.1. Lentivirus
Lentiviral vectors are a popular vector for CNS gene therapy as
they result in a long-lasting gene expression within neurons
without inducing a signiﬁcant host immune response (Abordo-
Adesida et al., 2005). They permit a transgene capacity of ~9 kb,
which is 2e3 times larger than AAVs. As lentivirus can integrate
into the genome there is a hypothetical risk of insertional muta-
genesis. To address potential concerns regarding chromosomal
mutagenesis owing to the insertion of viral genes non-integrating
constructs have been developed (Rahim et al., 2009; Wanisch and
Yanez-Munoz, 2009). Lentiviruses cannot be delivered systemi-
cally and are required to be injected directly into the brain. Due in
part to the large size of lentivirus (compared to AAV's) their diffu-
sion through the extracellular space is constrained and therefore
the spread of virus is highly restricted. In non-human primate
brain, injection of 1 ml into the visual cortex of a lentivirus resulted
in protein expression in the majority of neurons within 750 mm
radius of the injection site (Lerchner et al., 2014). To achieve
appropriate cortical coverage injections should be delivered within
a distance of 1.5 mm from each other. Therefore lentiviruses are a
more favourable choice for a channelopathywith a focal rather than
global pathology.
4.2. AAVs
AAVs are currently the preferred gene delivery vector for
treatment of CNS disorders (Blessing and Deglon, 2016; Choudhury
et al., 2016a). They provide long-term transgene expression with
minimal pathogenicity. There are numerous AAV serotypes and
these can have different tropisms and distributions (Wu et al.,
2006). AAVedelivered DNA usually exists in extrachromosomal
episomes, although under rare circumstances it can integrate intoPlease cite this article in press as: Wykes, R.C., Lignani, G., Gene therapy a
Neuropharmacology (2017), http://dx.doi.org/10.1016/j.neuropharm.2017the genome (High and Aubourg, 2011). As with lentiviruses there
therefore exists a potential risk for insertional mutagenesis. Some
AAV serotypes have a relatively high natural immunity (Zaiss and
Muruve, 2005). Neutralising antibodies can prevent brain trans-
duction (Boutin et al., 2010), therefore AAV serotypes for which the
prevalence in the human population is low or non-existent will be
required. Additionally acquired immunity could potentially
complicate repeated treatment. However these concerns have not
stopped clinical trials using these viruses for CNS disorders (Marks
et al., 2010; LeWitt et al., 2011). The most signiﬁcant shortcoming of
AAVs may be their small payload capacity (~4.5 kb of DNA), which
will preclude them from applications where delivery of large genes
or regulatory sequences is required. Importantlymore efﬁcient self-
complementary design AAV with great clinical efﬁcacy are even
more restrictive to the payload (2.2 kb) (Armbruster et al., 2016).
4.3. Promoters
Many experimental gene therapy studies utilise strong promo-
tors in their viral vectors such as cytomegalovirus (CMV) to drive
high transgene expression. In order to ﬁt in the viral vectors func-
tional fragments of promoters are often used instead the full-length
promoters. Dependent on the type or serotype of virus used rela-
tively speciﬁc expression in subpopulations of neurons can be
achieved. However the viral tropism for subpopulations of neurons
may not be consistent across species and raises concerns for
translation. We have previously reported that lentiviral delivery of
a transgene under the CMV promotor to rat motor cortex results in
preferential transduction of pyramidal (excitatory) neurones
(Wykes et al., 2012). However a different study, also using a lenti-
virus with a CMV promotor reported preferred transduction of glial
cells when the virus was injected into non-human primate cortex
(Lerchner et al., 2014). Depending on your gene therapy strategy it
may be crucial to restrict expression of your transgene to a
particular type of neuron. This could be relatively broad, for
example expression only in either excitatory or inhibitory neuro-
nes. Or it may be necessary to be more speciﬁc and to discriminate
between different subtypes of neurones for example parvalbumin
or somatostatin positive inhibitory neurons. To achieve speciﬁc
expression in excitatory glutamatergic neurons the CaMKIIa pro-
motor is usually employed. To target GABAergic interneurons
glutamate decarboxylase isoforms 65 or 67 promotors can be used,
however due to the large size of mammalian interneuron speciﬁc
promotor's popular viral vectors with limited payload capacity such
as AAVs are no longer an option. There are also concerns regarding
the speciﬁcity of these promoters in vivo (Mantoan Ritter et al.,
2016). To allow use of smaller viral vectors in combination with
interneuron speciﬁc promotors efforts have been made to ﬁnd al-
ternatives. These include expressing interneuron gene regulatory
sequences from the fugu ﬁsh to drive expression of transgenes in
mammalian brains (Nathanson et al., 2009) or inserting mDlx en-
hancers fromDLX5/6 genes to drive transgene expression restricted
to GABAergic interneurons in any vertebrate species
(Dimidschstein et al., 2016). If available the use of endogenous
promoter elements instead of exogenous promoters will be optimal
for the regulation of expression of an endogenous channel. For the
overexpression of exogenous therapeutic genes, such as a DREADD
or opsins, neuronal subtype speciﬁc promoters are more
appropriate.
4.4. Focal or global viral-mediated delivery of transgenes or
CRISPR-Cas
Although many viral-mediated approaches have worked very
well in experimental rodent studies there are additional factors tond editing: Novel potential treatments for neuronal channelopathies,
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is the large difference in brain size. Some channel genes undergo
differential splicingwhich varies among brain regions and neuronal
populations restricting the protein product of these disease-
associated mutations to discreet areas of the brain. In these cases
viral vectors can be injected directly into the area of the brain
required to reverse pathology. Many genetic channelopathies
however have a global pathology. For an effective treatment
widespread distribution of the vector will be required. Widespread
transgene expression could be achieved via multiple distributed
injections of virus (Simonato et al., 2013). Alternatively, injection
into densely packed cell bodies that project their axons across large
areas of the brain could result in extensive modulation of excit-
ability across the brain. For example, the majority of cholinergic
afferents to neocortex are from neurons in nucleus basalis. Tar-
geting cell bodies within the small area of the nucleus basalis with a
gene therapy could result in wide spread changes in acetylcholine
modulation throughout the cortex (Kalmbach et al., 2012). Vectors
could be injected into cerebrospinal ﬂuid to allow distribution
within the brain via the circulation. Alternatively some serotypes of
AAV have the ability to penetrate the blood brain barrier (BBB),
raising the possibility of a systemic administration of a virus that
targets neurons without the need for surgery (Gray et al., 2010).
AAV9 has been shown to cross the BBB and transduce large
numbers of neurons and glia in rodents (Duque et al., 2009; Foust
et al., 2009). Peripheral administration of viral vectors presents
several challenges to overcome before translation to humans can
occur. Systemic delivery will lead to transduction of cells outside
the CNS, such as those in the liver, heart and skeletal muscle.
Depending on the transgene selected for expression this could have
serious and signiﬁcant consequences for safety. To address these
concerns in addition to using neuronal speciﬁc promotors to drive
protein expression, micro-RNAmotifs can be added to the viral DNA
to minimise non-neuronal transduction. Incorporation of a liver
speciﬁc micro-RNA (miR-122) binding site into the backbone of the
AAV vector resulted in a dramatic reduction in the transduction of
liver cells without affecting transduction efﬁciency in other cell
types (Qiao et al., 2011). A similar strategy where several microRNA
binding sites designed to repress AAV expression outside of the CNS
were incorporated into the AAV9 vector resulted in high trans-
duction efﬁciency in the CNS and low transduction efﬁciency in
peripheral organs following intravascular delivery (Xie et al., 2011).
Intense screening of naturally occurring, chimeric, or engineered
AAV capsids with these desired characteristics, widespread CNS
transduction with minimal transgene expression in off-target or-
gans following intravenous injection, has resulted in AAV variants
such as AAV2g9 (Murlidharan et al., 2016), AAV-PHP.B (Deverman
et al., 2016; Jackson et al., 2016) or AAV-B1 (Choudhury et al.,
2016b). These new generation of AAVs are capable of efﬁcient
widespread transfer of genes throughout the CNS following sys-
temic injection.
4.5. Control of transgene expression
With the viral vector approaches previously discussed there is
no control for transgene expression once a neuron has been
transduced. As some ion channels undergo age-dependent changes
in expression the ability to switch on or off the transgene of interest
may be useful in the treatment of channelopathies where the pa-
thology is only apparent at certain ages. In fact it may be prudent to
discontinue expression of the therapeutic transgene once tran-
scription of the faulty gene ceases. For these cases the use of pro-
motors that can be induced in response to oral drugs can be used
(Naidoo and Young, 2012). Currently these inducible promoters rely
on antibiotic drugs and long-term use of these is undesirable,Please cite this article in press as: Wykes, R.C., Lignani, G., Gene therapy a
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diseases such as acne (Bienenfeld et al., 2017). Therefore the
development of non-antibiotic new molecules to induce promoter
activity will be preferable.
5. When should gene therapy be delivered?
Of critical relevance to treat a channelopathy will be when to
deliver the gene therapy. For gene editing therapies aimed at
reversing the mutation underlying a severe channelopathy such as
Dravet Syndrome, treatment may have to occur early in develop-
ment. Dravet syndrome is mostly due to heterozygous single
nucleotide mutations of the SCN1A gene (Brunklaus and Zuberi,
2014). Children with Dravet syndrome suffer from drug-resistant
seizures, intellectual disability, behaviour and sleep problems
(Wirrell, 2016). Once the formation of abnormal neuronal circuits
during critical periods of development occurs, as a consequence, of
the mutated ion channel, it is unlikely that a gene editing therapy
aimed at reversing this mutation alone will be effective at treating
all the symptoms of the disease if administered at a later stage in
development (Moody and Bosma, 2005; Lai and Jan 2006). In
contrast, in an adult brain, treatment of a channelopathy with a
milder phenotype, where brain behaviour is relatively normal in
between episodic attacks, is more likely to be amenable to a wider
range of gene therapy strategies. Gene therapy approaches can be
administered at both the germline and somatic genome level.
5.1. Germline genetic correction
Gene editing at the germline level could be the perfect treat-
ment to eradicate inherited neurological channelopathies as well as
other monogenic diseases (Baltimore et al., 2015; Vassena et al.,
2016). This approach is permanent and will be passed on to
further generations. Three different germline gene editing ap-
proaches are possible. 1. Gene editing in embryos before implan-
tation. 2. Male and/or female germ cell modiﬁcation. 3. iPS cells
editing and differentiation (Vassena et al., 2016). CRISPR/Cas9
mediated gene editing for all these processes is relatively simple
and efﬁcient. The use of CRISPR/Cas9 to correct genes in embryos
has already been published (Liang et al., 2015; Kang et al., 2016) and
new studies are ongoing (Callaway, 2016a, b). This presents how-
ever several ethical concerns and technical limitations. The ability
to change DNA at germline level permits modiﬁcation of an or-
ganism before its birth. Ethical debate surrounding these issues
both in the scientiﬁc community and wider public are ongoing
(Evitt et al., 2015; Flotte, 2015; Lanphier et al., 2015). Technically the
biggest hurdle to overcome for gene editing with CRISPR/Cas9 at
the germline level will be to prevent off-targets effects. Unwanted
changes in other genes due to similarity with the target sequence
must be avoided (Kleinstiver et al., 2016).
Germline gene correction of mutations could potentially eradi-
cate early-childhood devastating diseases such as Dravet Syndrome
by preventing the development of the widespread network circuits
abnormalities that lead to severe epilepsy, cognitive deﬁcits and
autistic behaviours (Brunklaus and Zuberi, 2014). This approach can
also be used to treat channelopathies where expression of the
protein is not only restricted to the brain. Timothy syndrome is a
multi-organ system channelopathy due to gain of function muta-
tions in the CACNA1C gene coding for the calcium channel Cav1.2.
This disorder comprises long QT syndrome, autism, epilepsy,
development deﬁcits and immunodeﬁciency. Children mostly die
prematurely for cardiac ventricular ﬁbrillation (Heyes et al., 2015;
Imbrici et al., 2016). Due to enhanced safety and ethical concern
this approach is still far from clinical translation but could poten-
tially be a game changer in the future.nd editing: Novel potential treatments for neuronal channelopathies,
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Fig. 1. Graphical representation of a developmental time course, indicating when gene therapy and gene editing interventions to treat a neuronal channelopathy are most likely to
be effective. An ion channel mutation may result in abnormal developmental of the brain or circuit alterations. The optimal gene editing or gene therapy strategy will depend when
during development they are delivered. Orange: germline intervention; blue: somatic genome intervention.
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Gene therapies on somatic cells imply that the treatments will
be only for that patient and will not pass to offspring. These ap-
proaches can be applied at late-embryonic, neonatal or adult stage.
The earlier the developmental stage, the easier it will be to target
large brain regions. At an early developmental stage gene editing
with CRISPR/Cas9 can be used to achieve gene correction (Suzuki
et al., 2016). Once neuronal circuits are already established, clas-
sical gene therapy approaches to manipulate network excitability,
either constitutively by up or downregulating endogenous proteins
(overexpression of genes, siRNA, or CRISPR/dCas9); or on demand
using optogenetics or chemogenetics are more appropriate as they
have the ability to modulate network activity.6. Conclusions
Gene therapies for non-neurological diseases are now achieving
regulatory approval (Bryant et al., 2013; Gaudet et al., 2013). There
has been remarkable progress in the last decade advancing the
translational suitability of viral vectors and gene therapy for
application to neurological disorders. The AAVs and lentiviruses
that are currently used to deliver transgenes are increasingly reli-
able in terms of expressing the transgene, and data on long-term
safety are accumulating from several neurological diseases
(Simonato et al., 2013). Several clinical trials for degenerative
neurological disorders have been reported (O'Connor and Boulis,
2015) and although the clinical outcome of these initial trials
have usually failed to show efﬁcacy they have demonstrated that
delivery of gene therapies to the CNS is safe and well-tolerated
(Bartus et al., 2014; Palﬁ et al., 2014).
Channelopathies usually manifest with abrupt periods of
abnormal brain excitability. Decades of rodent experimental
research in the epilepsy ﬁeld has shown that gene therapy ap-
proaches can treat diseases of the brain that affect network excit-
ability and some of these strategies may start clinical trials in the
near future (Kullmann et al., 2014). Therefore adapting some of the
gene therapy strategies used to treat epilepsy may be useful in the
treatment of neuronal channelopathies.
Guide RNA-mediated CRISPReCas nucleases are powerful
technologies for the engineering of mammalian genomes. Distinct
approaches can be used to treat a channelopathy using a CRISPR-Please cite this article in press as: Wykes, R.C., Lignani, G., Gene therapy a
Neuropharmacology (2017), http://dx.doi.org/10.1016/j.neuropharm.2017Cas strategy: disruption of gene expression, thereby reducing
mutant protein levels; regulation of endogenous gene expression
and epigenetic modiﬁcations; and ﬁnally, the repair of point mu-
tations in a faulty gene, restoring normal function to the translated
protein. Further developments in CRISPR technology will permit
not only a novel treatment for neurological channelopathies but a
potential cure for these diseases.
An important consideration in terms of which gene therapy or
gene editing approach to take will be the time of intervention and
whether the mutation results in widespread alterations in brain
development and behaviours (Fig. 1). If it is possible to detect the
channelopathy before permeant abnormal changes in brain func-
tion develop then treatment using CRISPR/Cas9 will potentially be
the best therapy. However if the brain has developed and wired
differently as a consequence of the channelopathy then ‘ﬁxing’ the
mutated gene underlying the disease in adult neurons may not be
enough to fully reverse the pathology. In these cases classic gene
therapy approaches to suppress or augment neuronal excitability
are more likely to be therapeutically beneﬁcial. Gene therapy ap-
proaches that optogenetically or chemogenetically supress or ex-
cites neurons on-demand are particularly attractive options to treat
paroxysmal disorders.
Conﬂict of interest
The authors declare no conﬂict of interests.
Acknowledgments
RCW is funded by an Epilepsy Research UK (F1401) fellowship
and GL is funded by a Marie Skłodowska-Curie (658418) individual
fellowship.
References
Abordo-Adesida, E., Follenzi, A., Barcia, C., Sciascia, S., Castro, M.G., Naldini, L.,
Lowenstein, P.R., 2005. Stability of lentiviral vector-mediated transgene
expression in the brain in the presence of systemic antivector immune re-
sponses. Hum. Gene Ther. 16, 741e751.
Armbruster, B.N., Li, X., Pausch, M.H., Herlitze, S., Roth, B.L., 2007. Evolving the lock
to ﬁt the key to create a family of G protein-coupled receptors potently acti-
vated by an inert ligand. Proc. Natl. Acad. Sci. U. S. A. 104, 5163e5168.
Armbruster, N., Lattanzi, A., Jeavons, M., Van Wittenberghe, L., Gjata, B., Marais, T.,
Martin, S., Vignaud, A., Voit, T., Mavilio, F., Barkats, M., Buj-Bello, A., 2016.nd editing: Novel potential treatments for neuronal channelopathies,
.05.029
R.C. Wykes, G. Lignani / Neuropharmacology xxx (2017) 1e108Efﬁcacy and biodistribution analysis of intracerebroventricular administration
of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular
atrophy. Mol. Ther. Methods Clin. Dev. 3, 16060.
Armstrong, C., Krook-Magnuson, E., Oijala, M., Soltesz, I., 2013. Closed-loop opto-
genetic intervention in mice. Nat. Protoc. 8, 1475e1493.
Assaf, F., Schiller, Y., 2016. The antiepileptic and ictogenic effects of optogenetic
neurostimulation of PV-expressing interneurons. J. Neurophysiol. 116,
1694e1704.
Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R.A., Church, G., Corn, J.E.,
Daley, G.Q., Doudna, J.A., Fenner, M., Greely, H.T., Jinek, M., Martin, G.S.,
Penhoet, E., Puck, J., Sternberg, S.H., Weissman, J.S., Yamamoto, K.R., 2015.
Biotechnology. A prudent path forward for genomic engineering and germline
gene modiﬁcation. Science 348, 36e38.
Bartus, R.T., Weinberg, M.S., Samulski, R.J., 2014. Parkinson's disease gene therapy:
success by design meets failure by efﬁcacy. Mol. Ther. 22, 487e497.
Berglind, F., Ledri, M., Sorensen, A.T., Nikitidou, L., Melis, M., Bielefeld, P., Kirik, D.,
Deisseroth, K., Andersson, M., Kokaia, M., 2014. Optogenetic inhibition of
chemically induced hypersynchronized bursting in mice. Neurobiol. Dis. 65,
133e141.
Bernard, C., Anderson, A., Becker, A., Poolos, N.P., Beck, H., Johnston, D., 2004. Ac-
quired dendritic channelopathy in temporal lobe epilepsy. Science 305,
532e535.
Bienenfeld, A., Nagler, A.R., Orlow, S.J., 2017. Oral antibacterial therapy for acne
vulgaris: an evidence-based review. Am. J. Clin. Dermatol 1e22. http://
dx.doi.org/10.1007/s40257-017-0267-z.
Blessing, D., Deglon, N., 2016. Adeno-associated virus and lentivirus vectors: a
reﬁned toolkit for the central nervous system. Curr. Opin. Virol. 21, 61e66.
Blits, B., Petry, H., 2016. Perspective on the road toward gene therapy for Parkinson's
disease. Front. Neuroanat. 10, 128.
Boison, D., 2010. Inhibitory RNA in epilepsy: research tools and therapeutic per-
spectives. Epilepsia 51, 1659e1668.
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M.F.,
Masurier, C., 2010. Prevalence of serum IgG and neutralizing factors against
adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population:
implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704e712.
Bovolenta, R., Zucchini, S., Paradiso, B., Rodi, D., Merigo, F., Navarro Mora, G.,
Osculati, F., Berto, E., Marconi, P., Marzola, A., Fabene, P.F., Simonato, M., 2010.
Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-
associated neuroinﬂammation and reduces spontaneous recurrent seizures.
J. Neuroinﬂammation 7, 81.
Brunklaus, A., Zuberi, S.M., 2014. Dravet syndromeefrom epileptic encephalopathy
to channelopathy. Epilepsia 55, 979e984.
Bryant, L.M., Christopher, D.M., Giles, A.R., Hinderer, C., Rodriguez, J.L., Smith, J.B.,
Traxler, E.A., Tycko, J., Wojno, A.P., Wilson, J.M., 2013. Lessons learned from the
clinical development and market authorization of Glybera. Hum. Gene Ther.
Clin. Dev. 24, 55e64.
Callaway, E., 2016a. UK scientists gain licence to edit genes in human embryos.
Nature 530, 18.
Callaway, E., 2016b. Gene-editing research in human embryos gains momentum.
Nature 532, 289e290.
Chiang, C.C., Ladas, T.P., Gonzalez-Reyes, L.E., Durand, D.M., 2014. Seizure suppres-
sion by high frequency optogenetic stimulation using in vitro and in vivo ani-
mal models of epilepsy. Brain Stimul. 7, 890e899.
Choong, C.J., Baba, K., Mochizuki, H., 2016. Gene therapy for neurological disorders.
Expert Opin. Biol. Ther. 16, 143e159.
Choudhury, S.R., Hudry, E., Maguire, C.A., Sena-Esteves, M., Breakeﬁeld, X.O.,
Grandi, P., 2016. Viral vectors for therapy of neurologic diseases. Neurophar-
macology 1e18 pii: S0028-3908(16)30048-X. http://dx.doi/10.1016/j.
neuropharm.2016.02.013 [Epub ahead of print].
Choudhury, S.R., Fitzpatrick, Z., Harris, A.F., Maitland, S.A., Ferreira, J.S., Zhang, Y.,
Ma, S., Sharma, R.B., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Alonso, L.C.,
Punzo, C., Wagner, K.R., Maguire, C.A., Kotin, R.M., Martin, D.R., Sena-
Esteves, M., 2016b. Vivo selection yields AAV-B1 capsid for central nervous
system and muscle gene therapy. Mol. Ther. 24, 1247e1257.
Chu, V.T., Weber, T., Wefers, B., Wurst, W., Sander, S., Rajewsky, K., Kuhn, R., 2015.
Increasing the efﬁciency of homology-directed repair for CRISPR-Cas9-induced
precise gene editing in mammalian cells. Nat. Biotechnol. 33, 543e548.
Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W.,
Marrafﬁni, L.A., Zhang, F., 2013. Multiplex genome engineering using CRISPR/
Cas systems. Science 339, 819e823.
Cox, D.B., Platt, R.J., Zhang, F., 2015. Therapeutic genome editing: prospects and
challenges. Nat. Med. 21, 121e131.
Deisseroth, K., 2010. Controlling the brain with light. Sci. Am. 303, 48e55.
Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A.,
Wu, W.L., Yang, B., Huber, N., Pasca, S.P., Gradinaru, V., 2016. Cre-dependent
selection yields AAV variants for widespread gene transfer to the adult brain.
Nat. Biotechnol. 34, 204e209.
Dimidschstein, J., et al., 2016. A viral strategy for targeting and manipulating in-
terneurons across vertebrate species. Nat. Neurosci. 19, 1743e1749.
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.M., Fyfe, J.,
Moullier, P., Colle, M.A., Barkats, M., 2009. Intravenous administration of self-
complementary AAV9 enables transgene delivery to adult motor neurons.
Mol. Ther. 17, 1187e1196.
Evitt, N.H., Mascharak, S., Altman, R.B., 2015. Human germline CRISPR-cas modiﬁ-
cation: toward a regulatory framework. Am. J. Bioeth. 15, 25e29.Please cite this article in press as: Wykes, R.C., Lignani, G., Gene therapy a
Neuropharmacology (2017), http://dx.doi.org/10.1016/j.neuropharm.2017Fenno, L., Yizhar, O., Deisseroth, K., 2011. The development and application of
optogenetics. Annu. Rev. Neurosci. 34, 389e412.
Ferguson, S.M., Neumaier, J.F., 2012. Grateful DREADDs: engineered receptors reveal
how neural circuits regulate behavior. Neuropsychopharmacology 37, 296e297.
Flotte, T.R., 2015. Therapeutic germ line alteration: has CRISPR/cas9 technology
forced the question? Hum. Gene Ther. 26, 245e246.
Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M., Kaspar, B.K.,
2009. Intravascular AAV9 preferentially targets neonatal neurons and adult
astrocytes. Nat. Biotechnol. 27, 59e65.
Gaudet, D., Methot, J., Dery, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K.,
de Wal, J., Twisk, J., van den Bulk, N., Sier-Ferreira, V., van Deventer, S., 2013.
Efﬁcacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene
therapy for lipoprotein lipase deﬁciency: an open-label trial. Gene Ther. 20,
361e369.
Glorioso, J.C., Fink, D.J., 2004. Herpes vector-mediated gene transfer in treatment of
diseases of the nervous system. Annu. Rev. Microbiol. 58, 253e271.
Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.C., Samulski, R.J., McCown, T.J., Li, W.,
2010. Directed evolution of a novel adeno-associated virus (AAV) vector that
crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18,
570e578.
Haberman, R., Criswell, H., Snowdy, S., Ming, Z., Breese, G., Samulski, R., McCown, T.,
2002. Therapeutic liabilities of in vivo viral vector tropism: adeno-associated
virus vectors, NMDAR1 antisense, and focal seizure sensitivity. Mol. Ther. 6,
495e500.
Haberman, R.P., Samulski, R.J., McCown, T.J., 2003. Attenuation of seizures and
neuronal death by adeno-associated virus vector galanin expression and
secretion. Nat. Med. 9, 1076e1080.
Heidenreich, M., Zhang, F., 2016. Applications of CRISPR-Cas systems in neurosci-
ence. Nat. Rev. Neurosci. 17, 36e44.
Heyes, S., Pratt, W.S., Rees, E., Dahimene, S., Ferron, L., Owen, M.J., Dolphin, A.C.,
2015. Genetic disruption of voltage-gated calcium channels in psychiatric and
neurological disorders. Prog. Neurobiol. 134, 36e54.
High, K.A., Aubourg, P., 2011. rAAV human trial experience. Methods Mol. Biol. 807,
429e457.
Hilton, I.B., D'Ippolito, A.M., Vockley, C.M., Thakore, P.I., Crawford, G.E., Reddy, T.E.,
Gersbach, C.A., 2015. Epigenome editing by a CRISPR-Cas9-based acetyl-
transferase activates genes from promoters and enhancers. Nat. Biotechnol. 33,
510e517.
Horvath, P., Barrangou, R., 2010. CRISPR/Cas, the immune system of bacteria and
archaea. Science 327, 167e170.
Imbrici, P., Liantonio, A., Camerino, G.M., De Bellis, M., Camerino, C., Mele, A.,
Giustino, A., Pierno, S., De Luca, A., Tricarico, D., Desaphy, J.F., Conte, D., 2016.
Therapeutic approaches to genetic ion channelopathies and perspectives in
drug discovery. Front. Pharmacol. 7, 121.
Incontro, S., Asensio, C.S., Edwards, R.H., Nicoll, R.A., 2014. Efﬁcient, complete
deletion of synaptic proteins using CRISPR. Neuron 83, 1051e1057.
Jackson, K.L., Dayton, R.D., Klein, R.L., 2016. Gene vector 'magic bullet': targeted
expression in the central nervous system after peripheral delivery using the
synapsin promoter. Expert Opin. Ther. Targets 20, 1153e1154.
Jimenez-Mateos, E.M., Engel, T., Merino-Serrais, P., McKiernan, R.C., Tanaka, K.,
Mouri, G., Sano, T., O'Tuathaigh, C., Waddington, J.L., Prenter, S., Delanty, N.,
Farrell, M.A., O'Brien, D.F., Conroy, R.M., Stallings, R.L., DeFelipe, J., Henshall, D.C.,
2012. Silencing microRNA-134 produces neuroprotective and prolonged
seizure-suppressive effects. Nat. Med. 18, 1087e1094.
Kalmbach, A., Hedrick, T., Waters, J., 2012. Selective optogenetic stimulation of
cholinergic axons in neocortex. J. Neurophysiol. 107, 2008e2019.
Kang, X., He, W., Huang, Y., Yu, Q., Chen, Y., Gao, X., Sun, X., Fan, Y., 2016. Introducing
precise genetic modiﬁcations into human 3PN embryos by CRISPR/Cas-
mediated genome editing. J. Assist. Reprod. Genet. 33, 581e588.
Katzel, D., Nicholson, E., Schorge, S., Walker, M.C., Kullmann, D.M., 2014. Chemical-
genetic attenuation of focal neocortical seizures. Nat. Commun. 5, 3847.
Kim, H., Kim, J.S., 2014. A guide to genome engineering with programmable nu-
cleases. Nat. Rev. Genet. 15, 321e334.
Kleinstiver, B.P., Pattanayak, V., Prew, M.S., Tsai, S.Q., Nguyen, N.T., Zheng, Z.,
Joung, J.K., 2016. High-ﬁdelity CRISPR-Cas9 nucleases with no detectable
genome-wide off-target effects. Nature 529, 490e495.
Krook-Magnuson, E., Armstrong, C., Oijala, M., Soltesz, I., 2013. On-demand opto-
genetic control of spontaneous seizures in temporal lobe epilepsy. Nat. Com-
mun. 4, 1376.
Krook-Magnuson, E., Gelinas, J.N., Soltesz, I., Buzsaki, G., 2015. Neuroelectronics and
biooptics: closed-loop technologies in neurological disorders. JAMA Neurol. 72,
823e829.
Krook-Magnuson, E., Szabo, G.G., Armstrong, C., Oijala, M., Soltesz, I., 2014. Cere-
bellar directed optogenetic intervention inhibits spontaneous hippocampal
seizures in a mouse model of temporal lobe epilepsy. eNeuro 1.
Kros, L., Rooda, O.H., De Zeeuw, C.I., Hoebeek, F.E., 2015. Controlling cerebellar
output to treat refractory epilepsy. Trends Neurosci. 38, 787e799.
Kullmann, D.M., 2010. Neurological channelopathies. Annu. Rev. Neurosci. 33,
151e172.
Kullmann, D.M., Waxman, S.G., 2010. Neurological channelopathies: new insights
into disease mechanisms and ion channel function. J. Physiol. 588, 1823e1827.
Kullmann, D.M., Schorge, S., Walker, M.C., Wykes, R.C., 2014. Gene therapy in
epilepsy-is it time for clinical trials? Nat. Rev. Neurol. 10, 300e304.
Ladas, T.P., Chiang, C.C., Gonzalez-Reyes, L.E., Nowak, T., Durand, D.M., 2015. Seizure
reduction through interneuron-mediated entrainment using low frequencynd editing: Novel potential treatments for neuronal channelopathies,
.05.029
R.C. Wykes, G. Lignani / Neuropharmacology xxx (2017) 1e10 9optical stimulation. Exp. Neurol. 269, 120e132.
Lai, H.C., Jan, L.Y., 2006. The distribution and targeting of neuronal voltage-gated ion
channels. Nat. Rev. Neurosci. 7, 548e562.
Lanphier, E., Urnov, F., Haecker, S.E., Werner, M., Smolenski, J., 2015. Don't edit the
human germ line. Nature 519, 410e411.
Ledri, L.N., Melin, E., Christiansen, S.H., Gotzsche, C.R., Cifra, A., Woldbye, D.P.,
Kokaia, M., 2016. Translational approach for gene therapy in epilepsy: model
system and unilateral overexpression of neuropeptide Y and Y2 receptors.
Neurobiol. Dis. 86, 52e61.
Lee, H.B., Sundberg, B.N., Sigafoos, A.N., Clark, K.J., 2016. Genome engineering with
TALE and CRISPR systems in neuroscience. Front. Genet. 7, 47.
Lerche, H., Shah, M., Beck, H., Noebels, J., Johnston, D., Vincent, A., 2013. Ion
channels in genetic and acquired forms of epilepsy. J. Physiol. 591, 753e764.
Lerchner, W., Corgiat, B., Der Minassian, V., Saunders, R.C., Richmond, B.J., 2014.
Injection parameters and virus dependent choice of promoters to improve
neuron targeting in the nonhuman primate brain. Gene Ther. 21, 233e241.
LeWitt, P.A., et al., 2011. AAV2-GAD gene therapy for advanced Parkinson's disease:
a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10,
309e319.
Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., Lv, J., Xie, X., Chen, Y., Li, Y.,
Sun, Y., Bai, Y., Songyang, Z., Ma, W., Zhou, C., Huang, J., 2015. CRISPR/Cas9-
mediated gene editing in human tripronuclear zygotes. Protein Cell 6, 363e372.
Lin, E.J., Young, D., Baer, K., Herzog, H., During, M.J., 2006. Differential actions of NPY
on seizure modulation via Y1 and Y2 receptors: evidence from receptor
knockout mice. Epilepsia 47, 773e780.
Liu, J., Gao, C., Chen, W., Ma, W., Li, X., Shi, Y., Zhang, H., Zhang, L., Long, Y., Xu, H.,
Guo, X., Deng, S., Yan, X., Yu, D., Pan, G., Chen, Y., Lai, L., Liao, W., Li, Z., 2016.
CRISPR/Cas9 facilitates investigation of neural circuit disease using human
iPSCs: mechanism of epilepsy caused by an SCN1A loss-of-function mutation.
Transl. Psychiatry 6, e703.
Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E.,
Church, G.M., 2013. RNA-guided human genome engineering via Cas9. Science
339, 823e826.
Manfredsson, F.P., Mandel, R.J., 2010. Development of gene therapy for neurological
disorders. Discov. Med. 9, 204e211.
Mantoan Ritter, L., Macdonald, D.C., Ritter, G., Escors, D., Chiara, F., Cariboni, A.,
Schorge, S., Kullmann, D.M., Collins, M., 2016. Lentiviral expression of GAD67
and CCK promoter-driven opsins to target interneurons in vitro and in vivo.
J. Gene Med. 18, 27e37.
Marks Jr., W.J., et al., 2010. Gene delivery of AAV2-neurturin for Parkinson's disease:
a double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164e1172.
Martin, V.T., Lipton, R.B., 2008. Epidemiology and biology of menstrual migraine.
Headache 48 (Suppl. 3), S124eS130.
Maruyama, T., Dougan, S.K., Truttmann, M.C., Bilate, A.M., Ingram, J.R., Ploegh, H.L.,
2015. Increasing the efﬁciency of precise genome editing with CRISPR-Cas9 by
inhibition of nonhomologous end joining. Nat. Biotechnol. 33, 538e542.
Mazzuferi, M., Kumar, G., van Eyll, J., Danis, B., Foerch, P., Kaminski, R.M., 2013. Nrf2
defense pathway: experimental evidence for its protective role in epilepsy. Ann.
Neurol. 74, 560e568.
McClelland, S., Flynn, C., Dube, C., Richichi, C., Zha, Q., Ghestem, A., Esclapez, M.,
Bernard, C., Baram, T.Z., 2011. Neuron-restrictive silencer factor-mediated hy-
perpolarization-activated cyclic nucleotide gated channelopathy in experi-
mental temporal lobe epilepsy. Ann. Neurol. 70, 454e464.
McCown, T.J., 2006. Adeno-associated virus-mediated expression and constitutive
secretion of galanin suppresses limbic seizure activity in vivo. Mol. Ther. 14,
63e68.
McMahon, M.A., Cleveland, D.W., 2017. Gene therapy: gene-editing therapy for
neurological disease. Nat. Rev. Neurol. 13, 7e9.
Moody, W.J., Bosma, M.M., 2005. Ion channel development, spontaneous activity,
and activity-dependent development in nerve and muscle cells. Physiol. Rev.
85, 883e941.
Murlidharan, G., Sakamoto, K., Rao, L., Corriher, T., Wang, D., Gao, G., Sullivan, P.,
Asokan, A., 2016. CNS-restricted transduction and CRISPR/cas9-mediated gene
deletion with an engineered AAV vector. Mol. Ther. Nucleic Acids 5, e338.
Naidoo, J., Young, D., 2012. Gene regulation systems for gene therapy applications in
the central nervous system. Neurol. Res. Int. 2012, 595410.
Nakade, S., Tsubota, T., Sakane, Y., Kume, S., Sakamoto, N., Obara, M., Daimon, T.,
Sezutsu, H., Yamamoto, T., Sakuma, T., Suzuki, K.T., 2014. Microhomology-
mediated end-joining-dependent integration of donor DNA in cells and animals
using TALENs and CRISPR/Cas9. Nat. Commun. 5, 5560.
Naldini, L., 2015. Gene therapy returns to centre stage. Nature 526, 351e360.
Nathanson, J.L., Jappelli, R., Scheeff, E.D., Manning, G., Obata, K., Brenner, S.,
Callaway, E.M., 2009. Short promoters in viral vectors drive selective expression
in mammalian inhibitory neurons, but do not restrict activity to speciﬁc
inhibitory cell-types. Front. Neural Circuits 3, 19.
Niu, Y., et al., 2014. Generation of gene-modiﬁed cynomolgus monkey via Cas9/
RNA-mediated gene targeting in one-cell embryos. Cell 156, 836e843.
Noe, F., Nissinen, J., Pitkanen, A., Gobbi, M., Sperk, G., During, M., Vezzani, A., 2007.
Gene therapy in epilepsy: the focus on NPY. Peptides 28, 377e383.
O'Connor, D.M., Boulis, N.M., 2015. Gene therapy for neurodegenerative diseases.
Trends Mol. Med. 21, 504e512.
Palﬁ, S., et al., 2014. Long-term safety and tolerability of ProSavin, a lentiviral vector-
based gene therapy for Parkinson's disease: a dose escalation, open-label, phase
1/2 trial. Lancet 383, 1138e1146.
Paradiso, B., Zucchini, S., Su, T., Bovolenta, R., Berto, E., Marconi, P., Marzola, A.,Please cite this article in press as: Wykes, R.C., Lignani, G., Gene therapy a
Neuropharmacology (2017), http://dx.doi.org/10.1016/j.neuropharm.2017Navarro Mora, G., Fabene, P.F., Simonato, M., 2011. Localized overexpression of
FGF-2 and BDNF in hippocampus reduces mossy ﬁber sprouting and sponta-
neous seizures up to 4 weeks after pilocarpine-induced status epilepticus.
Epilepsia 52, 572e578.
Paradiso, B., Marconi, P., Zucchini, S., Berto, E., Binaschi, A., Bozac, A., Buzzi, A.,
Mazzuferi, M., Magri, E., Navarro Mora, G., Rodi, D., Su, T., Volpi, I., Zanetti, L.,
Marzola, A., Manservigi, R., Fabene, P.F., Simonato, M., 2009. Localized delivery
of ﬁbroblast growth factor-2 and brain-derived neurotrophic factor reduces
spontaneous seizures in an epilepsy model. Proc. Natl. Acad. Sci. U. S. A. 106,
7191e7196.
Paz, J.T., Davidson, T.J., Frechette, E.S., Delord, B., Parada, I., Peng, K., Deisseroth, K.,
Huguenard, J.R., 2013. Closed-loop optogenetic control of thalamus as a tool for
interrupting seizures after cortical injury. Nat. Neurosci. 16, 64e70.
Pei, Y., Dong, S., Roth, B.L., 2010. Generation of designer receptors exclusively
activated by designer drugs (DREADDs) using directed molecular evolution.
Curr. Protoc. Neurosci. 33. Chapter 4:Unit 4.
Qi, L.S., Larson, M.H., Gilbert, L.A., Doudna, J.A., Weissman, J.S., Arkin, A.P., Lim, W.A.,
2013. Repurposing CRISPR as an RNA-guided platform for sequence-speciﬁc
control of gene expression. Cell 152, 1173e1183.
Qiao, C., Yuan, Z., Li, J., He, B., Zheng, H., Mayer, C., Li, J., Xiao, X., 2011. Liver-speciﬁc
microRNA-122 target sequences incorporated in AAV vectors efﬁciently inhibits
transgene expression in the liver. Gene Ther. 18, 403e410.
Rahim, A.A., Wong, A.M., Howe, S.J., Buckley, S.M., Acosta-Saltos, A.D., Elston, K.E.,
Ward, N.J., Philpott, N.J., Cooper, J.D., Anderson, P.N., Waddington, S.N.,
Thrasher, A.J., Raivich, G., 2009. Efﬁcient gene delivery to the adult and fetal CNS
using pseudotyped non-integrating lentiviral vectors. Gene Ther. 16, 509e520.
Raol, Y.H., Lund, I.V., Bandyopadhyay, S., Zhang, G., Roberts, D.S., Wolfe, J.H.,
Russek, S.J., Brooks-Kayal, A.R., 2006. Enhancing GABA(A) receptor alpha 1
subunit levels in hippocampal dentate gyrus inhibits epilepsy development in
an animal model of temporal lobe epilepsy. J. Neurosci. 26, 11342e11346.
Richichi, C., Lin, E.J., Stefanin, D., Colella, D., Ravizza, T., Grignaschi, G., Veglianese, P.,
Sperk, G., During, M.J., Vezzani, A., 2004. Anticonvulsant and antiepileptogenic
effects mediated by adeno-associated virus vector neuropeptide Y expression in
the rat hippocampus. J. Neurosci. 24, 3051e3059.
Roth, B.L., 2016. DREADDs for neuroscientists. Neuron 89, 683e694.
Rubio, A., Luoni, M., Giannelli, S.G., Radice, I., Iannielli, A., Cancellieri, C., Di
Berardino, C., Regalia, G., Lazzari, G., Menegon, A., Taverna, S., Broccoli, V., 2016.
Rapid and efﬁcient CRISPR/Cas9 gene inactivation in human neurons during
human pluripotent stem cell differentiation and direct reprogramming. Sci. Rep.
6, 37540.
Ryan, D.P., Ptacek, L.J., 2010. Episodic neurological channelopathies. Neuron 68,
282e292.
Sander, J.D., Joung, J.K., 2014. CRISPR-Cas systems for editing, regulating and tar-
geting genomes. Nat. Biotechnol. 32, 347e355.
Simonato, M., 2014. Gene therapy for epilepsy. Epilepsy Behav. 38, 125e130.
Simonato, M., Bennett, J., Boulis, N.M., Castro, M.G., Fink, D.J., Goins, W.F., Gray, S.J.,
Lowenstein, P.R., Vandenberghe, L.H., Wilson, T.J., Wolfe, J.H., Glorioso, J.C., 2013.
Progress in gene therapy for neurological disorders. Nat. Rev. Neurol. 9,
277e291.
Snowball, A., Schorge, S., 2015. Changing channels in pain and epilepsy: exploiting
ion channel gene therapy for disorders of neuronal hyperexcitability. FEBS Lett.
589, 1620e1634.
Soper, C., Wicker, E., Kulick, C.V., N'Gouemo, P., Forcelli, P.A., 2016. Optogenetic
activation of superior colliculus neurons suppresses seizures originating in
diverse brain networks. Neurobiol. Dis. 87, 102e115.
Sorokin, J.M., Davidson, T.J., Frechette, E., Abramian, A.M., Deisseroth, K.,
Huguenard, J.R., Paz, J.T., 2017. Bidirectional control of generalized epilepsy
networks via rapid real-time switching of ﬁring mode. Neuron 93, 194e210.
Spillane, J., Kullmann, D.M., Hanna, M.G., 2016. Genetic neurological channelo-
pathies: molecular genetics and clinical phenotypes. J. Neurol. Neurosurg.
Psychiatry 87, 37e48.
Straub, C., Granger, A.J., Saulnier, J.L., Sabatini, B.L., 2014. CRISPR/Cas9-mediated
gene knock-down in post-mitotic neurons. PLoS One 9, e105584.
Sukhotinsky, I., Chan, A.M., Ahmed, O.J., Rao, V.R., Gradinaru, V., Ramakrishnan, C.,
Deisseroth, K., Majewska, A.K., Cash, S.S., 2013. Optogenetic delay of status
epilepticus onset in an in vivo rodent epilepsy model. PLoS One 8, e62013.
Suzuki, K., et al., 2016. In vivo genome editing via CRISPR/Cas9 mediated homology-
independent targeted integration. Nature 540, 144e149.
Swann, J.W., Rho, J.M., 2014. How is homeostatic plasticity important in epilepsy?
Adv. Exp. Med. Biol. 813, 123e131.
Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., Sur, M.,
Zhang, F., 2015. In vivo interrogation of gene function in the mammalian brain
using CRISPR-Cas9. Nat. Biotechnol. 33, 102e106.
Theoﬁlas, P., Brar, S., Stewart, K.A., Shen, H.Y., Sandau, U.S., Poulsen, D., Boison, D.,
2011. Adenosine kinase as a target for therapeutic antisense strategies in epi-
lepsy. Epilepsia 52, 589e601.
Vassena, R., Heindryckx, B., Peco, R., Pennings, G., Raya, A., Sermon, K., Veiga, A.,
2016. Genome engineering through CRISPR/Cas9 technology in the human
germline and pluripotent stem cells. Hum. Reprod. Update 22, 411e419.
Wagnon, J.L., Meisler, M.H., 2015. Recurrent and non-recurrent mutations of SCN8A
in epileptic encephalopathy. Front. Neurol. 6, 104.
Wanisch, K., Yanez-Munoz, R.J., 2009. Integration-deﬁcient lentiviral vectors: a slow
coming of age. Mol. Ther. 17, 1316e1332.
Wiedenheft, B., Sternberg, S.H., Doudna, J.A., 2012. RNA-guided genetic silencing
systems in bacteria and archaea. Nature 482, 331e338.nd editing: Novel potential treatments for neuronal channelopathies,
.05.029
R.C. Wykes, G. Lignani / Neuropharmacology xxx (2017) 1e1010Wirrell, E.C., 2016. Treatment of Dravet syndrome. Can. J. Neurol. Sci. 43 (Suppl. 3),
S13eS18.
Woldbye, D.P., Angehagen, M., Gotzsche, C.R., Elbrond-Bek, H., Sorensen, A.T.,
Christiansen, S.H., Olesen, M.V., Nikitidou, L., Hansen, T.V., Kanter-Schlifke, I.,
Kokaia, M., 2010. Adeno-associated viral vector-induced overexpression of
neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain
133, 2778e2788.
Wright, A.V., Nunez, J.K., Doudna, J.A., 2016. Biology and applications of CRISPR
systems: harnessing Nature's toolbox for genome engineering. Cell 164, 29e44.
Wu, Z., Asokan, A., Samulski, R.J., 2006. Adeno-associated virus serotypes: vector
toolkit for human gene therapy. Mol. Ther. 14, 316e327.
Wykes, R.C., Kullmann, D.M., Pavlov, I., Magloire, V., 2016. Optogenetic approaches
to treat epilepsy. J. Neurosci. Methods 260, 215e220.
Wykes, R.C., Heeroma, J.H., Mantoan, L., Zheng, K., MacDonald, D.C., Deisseroth, K.,Please cite this article in press as: Wykes, R.C., Lignani, G., Gene therapy a
Neuropharmacology (2017), http://dx.doi.org/10.1016/j.neuropharm.2017Hashemi, K.S., Walker, M.C., Schorge, S., Kullmann, D.M., 2012. Optogenetic and
potassium channel gene therapy in a rodent model of focal neocortical epilepsy.
Sci. Transl. Med. 4, 161ra152.
Xie, J., Xie, Q., Zhang, H., Ameres, S.L., Hung, J.H., Su, Q., He, R., Mu, X., Seher
Ahmed, S., Park, S., Kato, H., Li, C., Mueller, C., Mello, C.C., Weng, Z., Flotte, T.R.,
Zamore, P.D., Gao, G., 2011. MicroRNA-regulated, systemically delivered rAAV9:
a step closer to CNS-restricted transgene expression. Mol. Ther. 19, 526e535.
Xu, Z., Wang, Y., Chen, B., Xu, C., Wu, X., Wang, Y., Zhang, S., Hu, W., Wang, S., Guo, Y.,
Zhang, X., Luo, J., Duan, S., Chen, Z., 2016. Entorhinal principal neurons mediate
brain-stimulation treatments for epilepsy. EBioMedicine 14, 148e160.
Yang, Y., Walsh, C.E., 2005. Spliceosome-mediated RNA trans-splicing. Mol. Ther. 12,
1006e1012.
Zaiss, A.K., Muruve, D.A., 2005. Immune responses to adeno-associated virus vec-
tors. Curr. Gene Ther. 5, 323e331.nd editing: Novel potential treatments for neuronal channelopathies,
.05.029
